Abstract
This chapter serves as an introduction to the entire volume. A brief description of protein primary, secondary, and tertiary structure, as well as the importance of the appropriate folded structure for the safety and efficacy of protein pharmaceuticals, is presented. This is followed by an overview of the development life cycle for biotherapeutics, beginning with target identification, through candidate selection, process and formulation development, and commercialization.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dobsen CM (2004) Principles of protein folding, misfolding, and aggregation. Semin Cell Dev Biol 15:3–16
Mahler H-C, Friess W, Grauschopf U, Kiese S (2009) Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 98:2909–2934
Narhi LO, Jiang Y, Deshpande R, Kang S, Shultz J (2010) Approaches to control protein aggregation during bulk production. In: Wang W, Roberts CJ (eds) Aggregation of therapeutic proteins. Wiley, Hoboken
Pavlou AK, Belsey MJ (2005) The therapeutic antibody market to 2008. Eur J Pharm Biopharm 59:389–396
Walsh G (2010) Biopharmaceutical benchmarks. Nat Biotechnol 28:917–924
Wang W, Singh S, Zeng DL, King K, Nema S (2007) Antibody structure, instability and formulation. J Pharm Sci 96:1–26
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Narhi, L.O. (2013). Introduction. In: Narhi, L. (eds) Biophysics for Therapeutic Protein Development. Biophysics for the Life Sciences, vol 4. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4316-2_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4316-2_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4315-5
Online ISBN: 978-1-4614-4316-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)